新辅助化放疗和姑息性化疗在晚期胸腺肿瘤中的应用进展  

Neoadjuvant and palliative chemotherapy in advanced and metastatic thymoma and thymic carcinoma

作　　者：贾佳[1,2] 李月敏[1] 

机构地区：[1]解放军第309医院放疗科,北京100091 [2]河北北方学院研究生部,河北张家口075000

出　　处：《解放军医学院学报》2015年第11期1160-1162,F0003,共4页Academic Journal of Chinese PLA Medical School

基　　金：吴阶平医学基金资助项目(320.6750.14296);北京市首都临床特色应用研究项目(Z121107001012060)~~

摘　　要：胸腺瘤是一类具有广谱生物学行为的罕见肿瘤。对局部晚期胸腺瘤采用新辅助化放疗,可缩小肿瘤或降低分期,提高手术完整切除率。对于无手术指征或远处转移的胸腺瘤给予姑息性化放疗,有助于延长生存期和提高生活质量。最为广泛使用的化疗方案是以顺铂和蒽环类药物为基础的联合方案。近年来陆续尝试新一代化疗药物,包括紫杉醇、多西他赛、卡培他滨、吉西他滨和培美曲赛等,均显示一定疗效。Thymoma is a rare tumor with a broad spectrum of biological behavior. For locally advanced thymoma, neoadjuvant chemoradiotherapy can reduce tumor staging and improve surgical resection rate. For unresectable advanced thymomas or metastatic thymomas, palliative radiotherapy and chemotherapy can prolong survival and improve quality of life. The most widely used chemotherapy regimen is cisplatin and marcellomycin drug-based combination chemotherapy scheme. In recent years, a new generation of chemotherapeutic drugs has been tried continually in clinic, including paclitaxel, docetaxel, capecitabine, gemcitabine and alimta, which show a certain therapeutic effect.

关 键 词：胸腺瘤 新辅助化疗 同步化放疗 姑息性化疗 

分 类 号：R736.3[医药卫生—肿瘤]